Acceleration of the development of diabetes in obese diabetic (db/db) mice by nicotinamide: A comparison with its antidiabetic effects in non-obese diabetic mice

Metabolism: Clinical and Experimental

Volumn 49, Issue 12, 2000, Pages 1548-1554

  Piercy, V ^a   Toseland, C D N ^a   Turner, N C ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC OBESITY; DISEASE COURSE; DRUG EFFECT; FEMALE; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GLYCOSURIA; HYPERGLYCEMIA; INSULIN; ISLETS OF LANGERHANS; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; NIACINAMIDE; OBESITY; PANCREAS;

EID: 0034537622     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. The NOD mouse as a model of type 1 diabetes
2. The NOD mouse
3. Diabetic animal models
4. Molecular mechanisms of beta-cell destruction in IDDM: The role of nicotinamide
5. Preventative and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insinulitis
6. Early nicotinamide treatment in the NOD mouse: Effects on diabetes and insulinitis suppression and autoantibody levels
7. Inhibition of diabetes in non-obese diabetic mice by nicotinamide treatment for 5 weeks at the early age
8. Protection against alloxan diabetes
9. Protection against diabetes with nicotinamide
10. Nicotinamide - Biological actions and therapeutic potential in diabetes prevention, IDIG Workshop, Copenhagen, Denmark, December 4-5, 1992
11. Nicotinamide and prevention of insulin-dependent diabetes mellitus. Rationalae, effects, toxicology and clinical experiences. ENDIT Group
12. A multi-centre randomized trial of two different doses of nicotinamide in patients with recent onset type 1 diabetes (The IMDIAB VI)
13. Islet amyloid. Increased in A-cells, reduced B-cells and exocrine fibrosis: Quantitative changes in pancreas in type II diabetes
14. Islet pathology and the pathogenesis of type 1 and type 2 diabetes
15. Natural history of B-cell dysfunction in NIDDM
16. Cellular composition of the human diabetic pancreas
17. Introduction to diabetes
18. Role of insulin resistance in human disease
19. Development of the insulin secretory defect in genetically diabetic (db/db) mouse
20. Antidiabetic efficacy of BRL 49653, a potent orally active insulin sensitizing agent, assessed in the C57BL/KsJ db/db diabetic mouse by non invasive 1H NMR studies of urine
21. Potential benefits of inhibitors of advanced glycation end products in the progression of type II diabetes: A study with aminoguanidine in C57/BLKsJ diabetic mice
22. Aminoguanidine prevents diabetes induced arterial wall protein cross linking
23. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction
24. Nitric oxide toxicity in islet cells involves poly(ADP-ribose) polymerase activation and concomitant NAD+ depletion
25. Nicotinamide in type I diabetes. Mechanism of action revisited
26. Nicotinamide inhibits nitric oxide synthase mRNA induction on activated macrophages
27. Role of nitric oxide in obesity-induced beta cell disease
28. The harderian gland in autoimmune diabetes of the nonobese diabetic mouse
29. The pathogenesis of insulin dependent diabetes mellitus
30. Fatty acid-induced B-cell apoptosis: A link between obesity and diabetes
31. Aspects of the involvement of interleukin-1 and nitric oxide in the pathogenesis for insulin-dependent diabetes mellitus
32. Central nervous system nitric oxide synthase activity regulates insulin secretion and insulin action
33. NG-methyl-L-arginine, an inhibitor of nitric oxide synthase affects the central nervous system to produce peripheral hyperglycaemia in conscious rats
34. Insulin resistance following acute induction of hypertension with the nitric oxide synthase inhibitor L-NMMA in rats
35. NOD mouse colonies around the world - Recent fact and figures
36. A diet enriched in protein accelerates diabetes manifestation in NOD mice
37. The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: A 25-year review of deaths in patients under 20 years of age in the United Kingdom
38. Nicotinamide and insulin secretion in normal subjects
39. Nicotinamide and insulin sensitivity
40. Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas
41. Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM
42. Latent autoimmune diabetes mellitus in adults (LADA): The role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency
43. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA)